Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer.
OBJECTIVE
To characterize the variation in adherence to quality measures of external beam radiotherapy (EBRT) for localized prostate cancer and its relation to patient and provider characteristics in a population-based, representative sample of U.S. men.


METHODS
We evaluated EBRT quality measures proposed by a RAND expert panel of physicians among men aged >or=65 years diagnosed between 2000 and 2002 with localized prostate cancer and treated with primary EBRT using data from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare program. We assessed the adherence to five EBRT quality measures that were amenable to analysis using SEER-Medicare data: (1) use of conformal RT planning; (2) use of high-energy (>10-MV) photons; (3) use of custom immobilization; (4) completion of two follow-up visits with a radiation oncologist in the year after therapy; and (5) radiation oncologist board certification.


RESULTS
Of the 11,674 patients, 85% had received conformal RT planning, 75% had received high-energy photons, and 97% had received custom immobilization. One-third of patients had completed two follow-up visits with a radiation oncologist, although 91% had at least one visit with a urologist or radiation oncologist. Most patients (85%) had been treated by a board-certified radiation oncologist.


CONCLUSIONS
The overall high adherence to EBRT quality measures masked substantial variation in geography, socioeconomic status in the area of residence, and teaching affiliation of the RT facility. Future research should examine the reasons for the variations in these measures and whether the variation is associated with important clinical outcomes.
Bekelman
Justin E
JE
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. bekelmaj@mskcc.org
Zelefsky
Michael J
MJ
Jang
Thomas L
TL
Basch
Ethan M
EM
Schrag
Deborah
D
D000368:Aged; D000369:Aged, 80 and over; D019983:Guideline Adherence / Q000592:standards*; D006784:Hospitals, Teaching / Q000592:standards; D006801:Humans; D016015:Logistic Models; D008297:Male; D017785:Photons / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D020266:Radiotherapy, Conformal / Q000592:standards*; D011882:Radiotherapy, High-Energy / Q000592:standards*; D018426:SEER Program / Q000592:standards; D012959:Socioeconomic Factors; D014481:United States
J Clin Epidemiol. 2000 Dec;53(12):1258-67
11146273
J Natl Cancer Inst. 2001 Apr 4;93(7):500
11287443
N Engl J Med. 2001 Sep 6;345(10):725-30
11547741
Int J Qual Health Care. 2001 Dec;13(6):475-80
11769750
J Natl Cancer Inst. 2002 Jun 5;94(11):835-44
12048271
Med Care. 2002 Aug;40(8 Suppl):IV-82-95
12187173
Cancer. 2003 Mar 15;97(6):1428-35
12627506
J Clin Oncol. 2003 May 15;21(10):1928-36
12743145
Med Care. 2003 Sep;41(9):1003-5
12972839
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1053-61
15234039
J Clin Oncol. 2004 Aug 1;22(15):2985-91
15284249
Med Care. 1993 Aug;31(8):732-48
8336512
Am J Epidemiol. 1998 Sep 1;148(5):475-86
9737560
Ethn Dis. 1999 Winter;9(1):111-25
10355480
J Urol. 2004 Nov;172(5 Pt 2):S13-6; discussion S17
15535436
Ethn Dis. 2005 Spring;15(2 Suppl 2):S31-3
15822835
J Urol. 2005 Aug;174(2):425-31
16006858
Cancer. 2005 Sep 1;104(5):985-92
16047332
Strahlenther Onkol. 2005 Sep;181(9):557-66
16170482
J Clin Oncol. 2005 Nov 1;23(31):7881-8
16204005
J Natl Cancer Inst. 2006 Jan 4;98(1):26-38
16391369
J Clin Oncol. 2006 Feb 1;24(4):626-34
16401682
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):322-3
16690426
J Clin Oncol. 2007 Jan 20;25(3):277-84
17159190
Med Care. 2007 May;45(5):401-9
17446826
Ann Intern Med. 2000 May 2;132(9):705-10
10787363
Am J Med. 2000 Jun 1;108(8):642-9
10856412
Med Care. 2003 Sep;41(9):1006-12
12972840
N Engl J Med. 2003 Oct 2;349(14):1350-9
14523144
J Gen Intern Med. 2004 Feb;19(2):146-55
15009794